SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences surges on plan to raise Rs 2,000 crore through redeemable NCDs

10 Sep 2014 Evaluate

Jubilant Life Sciences is currently trading at Rs 180.00, up by 4.10 points or 2.33% from its previous closing of Rs 175.90 on the BSE...

The scrip opened at Rs 177.50 and has touched a high and low of Rs 181.15 and Rs 177.50 respectively. So far 27907 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 1 has touched a 52 week high of Rs. 222.00 on 13-Jun-2014 and a 52 week low of Rs. 72.00 on 21-Oct-2013.

Last one week high and low of the scrip stood at Rs. 177.80 and Rs. 162.00 respectively. The current market cap of the company is Rs. 2801.76 crore.

The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 27.58% and 18.39% respectively.

Drug firm Jubilant Life Sciences has received its shareholders’ approval to raise Rs 2,000 crore through redeemable non-convertible debentures (NCDs) on a private placement basis or rights basis in one or more tranches. Additionally, the borrowing through debentures will be within the above overall borrowing limit of Rs 5,000 crore.

Jubilant Life Sciences is engaged in manufacture and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.

 

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×